Clinical

Dataset Information

0

A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

ABSTRACT: This is a multicenter, open-label study enrolling a total of up to 23 patients.

DISEASE(S): Metastatic Colorectal Cancer,Colon Cancer,Colorectal Neoplasms

PROVIDER: 2070218 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Clinical A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
| 2068504 | ecrin-mdr-crc
Unknown Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
| S-EPMC7268753 | biostudies-literature
Unknown Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer in China.
| S-EPMC12411481 | biostudies-literature
Unknown Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.
| S-EPMC7320929 | biostudies-literature
Unknown Five-year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma.
| S-EPMC8252056 | biostudies-literature
Unknown Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma.
| S-EPMC6549931 | biostudies-literature
Unknown Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
| S-EPMC10852367 | biostudies-literature
Unknown Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.
| S-EPMC9883304 | biostudies-literature
Unknown Optimal daratumumab-based regimen for patients with newly diagnosed and previously untreated multiple myeloma: systematic review and component network meta-analysis.
| S-EPMC12082950 | biostudies-literature
Unknown Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial.
| S-EPMC9227706 | biostudies-literature